Redeye is positive to the successful phase I outcome with SAN711 and raise our base case indicativel...
CirChem har meddelat att Mark- och miljödomstolen i Vänersborg har beviljat bolaget tillstånd för ut...
Starkt Q2-resultat Nettoomsättningen i kvartalet uppgick till 91,2 mkr vs vårt estimat om 81,7 mkr.
Redeye embraces the news regarding the OECD validation on GARDskin.
Redeye is encouraged by the news of today's record-breaking order from Amazon worth USD 1.
Redeye updates its estimates for the Q2 report, with slightly lower sales but a higher operating mar...
Redeye is encouraged to learn that ISR has signed an agreement with Catalent Inhalation to scale-up ...
Our analyst summarizes the investment case: “Eevia Health offer organic plant extracts for food nutr...
Redeye initiates coverage of Fuud, a Swedish serial acquirer in the functional food sector.
Redeye leaves a comment following Faron Pharmaceutical’s announcement earlier today of a placing of ...
Sedan noteringen har Candles Scandinavia levererat hög omsättningstillväxt och bolaget är väl positi...
On June 22, 2022, Fluicell announced that they have been selected as one out of ten most innovative ...
Redeye updates its view on Energy Save post its Q4’2021/22 report.
Redeye makes an adjustment to the project’s LOA based on results from BT-001’s phase I trial, part A...
Redeye is encouraged by the news from Evaxion concerning good pre-clinical results of EVX-03 and the...
Redeye comments on the news regarding ISAB's latest IRS order worth SEK 518,000.
Q2 report due on 15 July Dedicare is taking market share in a growing market New value range of SEK ...
We trim our growth assumptions Slower rental growth hedges against price fall 11x ’23e P/IFPM and 5...
Redeye comments on Energy Save’s Q4’21/22 report. The report showed strong growth and profitability ...
Bolaget genomförde en riktad emission i syfte att stärka ägarsidan vilket påverkade resultatet för Q...
